甘肃医药
甘肅醫藥
감숙의약
Gansu Medical Journal
2015年
11期
817-820
,共4页
美托洛尔%稳心颗粒%高血压心脏病%室性早搏
美託洛爾%穩心顆粒%高血壓心髒病%室性早搏
미탁락이%은심과립%고혈압심장병%실성조박
metoprolol%Wenxin premature ventricular beats granule%hypertensive heart disease
目的:对美托洛尔联合稳心颗粒治疗高血压心脏病室性早搏的临床疗效进行初评. 方法:在我院选取高血压心脏病室性早搏患者76例,随机将其分为察组和对照组,每组38不同药物的使用情况下血液流变学、临床疗效、不良反应发生率. 结果:两组患者的血液流变学相应指标均有所下降,其中观察组下降程度明显优于对照组,具有统计学意义(P<0.05);观察组在美托洛尔联合稳心颗粒治疗下,临床疗效明显优于对照组,具有统计学意义(P<0.05);两组的不良反应发生率相差不大,无统计学差异(P>0.05).结论:美托洛尔联合稳心颗粒治疗高血压心脏病室性早搏具有明显的临床疗效,安全可靠,不良反应较少,适合临床推广.
目的:對美託洛爾聯閤穩心顆粒治療高血壓心髒病室性早搏的臨床療效進行初評. 方法:在我院選取高血壓心髒病室性早搏患者76例,隨機將其分為察組和對照組,每組38不同藥物的使用情況下血液流變學、臨床療效、不良反應髮生率. 結果:兩組患者的血液流變學相應指標均有所下降,其中觀察組下降程度明顯優于對照組,具有統計學意義(P<0.05);觀察組在美託洛爾聯閤穩心顆粒治療下,臨床療效明顯優于對照組,具有統計學意義(P<0.05);兩組的不良反應髮生率相差不大,無統計學差異(P>0.05).結論:美託洛爾聯閤穩心顆粒治療高血壓心髒病室性早搏具有明顯的臨床療效,安全可靠,不良反應較少,適閤臨床推廣.
목적:대미탁락이연합은심과립치료고혈압심장병실성조박적림상료효진행초평. 방법:재아원선취고혈압심장병실성조박환자76례,수궤장기분위찰조화대조조,매조38불동약물적사용정황하혈액류변학、림상료효、불량반응발생솔. 결과:량조환자적혈액류변학상응지표균유소하강,기중관찰조하강정도명현우우대조조,구유통계학의의(P<0.05);관찰조재미탁락이연합은심과립치료하,림상료효명현우우대조조,구유통계학의의(P<0.05);량조적불량반응발생솔상차불대,무통계학차이(P>0.05).결론:미탁락이연합은심과립치료고혈압심장병실성조박구유명현적림상료효,안전가고,불량반응교소,괄합림상추엄.
Objective:To observe the clinical efficacy of treating hypertensive ventricular premature contraction patients by metoprolol combined with Wenxin granule. Methods:76 hypertensive patients with ventricular premature beats in our hospital were randomly divided Into observation group and control group, 38 cases in each group. The control group were treated with metoprolol, the observation group were treated with metoprolol combined with Wenxin granule in which blood rheology, clinical curative effect, adverse reaction rate were compared in two groups. Results:The indexes of blood rheologyin the two groups was decreased, the degree of decline in the observation group was significantly better than the contolgroup which the in difference was statistically significant (P<0.05). The clinical curative effect was significantly better in observation group than that in control group in which the difference was statistically significa nt (P<0.05). The incidence of adverse reactions in the two groups was similar, and no difference in statistics(P<0.05). Conclusion: Metoprolol combined with Wenxin granule in the treatment for hypertensive ventricular premature beats has obvious clinical curative effect, which is safe and reliable, less adverse reactions, suitable for clinical promotion.